In addition to being a lucrative time for venture funding, Boston tech companies made several new moves last week. Read on to find out these startups’ latest developments. This is the Built In Boston weekly refresh.
Inari secured $208M. Valued at $1.2 billion following its latest injection of funding, this Cambridge-based biotech company is advancing its platform and furthering its work. Inari developed a way to manipulate the genetics of seeds in an effort to make crops viable in different regions. Flagship Pioneering and existing investors led the round. [Built In Boston]
Aetion raised $110M. Its platform gathers data to provide medical professionals with critical product insights to help improve patient care. With the new funding from its Series C led by Warburg Pincus, Aetion is planning to further its platform, fuel international expansion in Europe and Asia and grow its commercial team. It’s currently hiring for positions based out of its Boston office. [Built In Boston]
Boston Tech Quote of the Week
Whoop is moving its HQ and building out its team. The company built a wearable wristband meant to monitor a user’s health surrounding sleep and fitness. Its new 121,000-square-foot headquarters in Kenmore Square will house 1,000 new employees across departments like engineering, data science, R&D, marketing and product when it opens next year. [Built In Boston]
Ginkgo Bioworks to go public via SPAC. Another company is moving to the public sector through merging with a special purpose acquisition company. By joining Soaring Eagle Acquisition, synthetic biology unicorn Gingko will reach a $15 billion valuation. The capital from the merge will go toward scaling its platform and hiring across dozens of Boston-based science and tech roles. [Built In Boston]
Euclid pulled in $8M. Focusing on improving care for those with cardiovascular disease, this healthtech company grabbed fresh Series A funding for its AI-powered detection software. The round was led by investors and will help Euclid to continue developing its tech. [Cardiovascular Business]